Coronavirus | New challenges for COVID-19 vaccine trials in India

With the daily cases coming down, many people who would have volunteered would not see the urgency now as earlier

January 09, 2021 06:48 pm | Updated 10:19 pm IST

The alternative:  Vaccine manufacturers can carry out phase-3 trials outside India and efficacy results from such trials would be accepted by the Indian regulator for vaccine approval.

The alternative: Vaccine manufacturers can carry out phase-3 trials outside India and efficacy results from such trials would be accepted by the Indian regulator for vaccine approval.

On January 1, Pune-based Serum Institute’s Covishield vaccine was granted permission for restricted use, while Bharat Biotech’s Covaxin got a similar approval the next day with certain other riders. With two vaccines now being greenlighted for restricted use, the four high-risk priority groups, beginning with frontline health-care workers, will soon begin getting vaccinated. Nearly 300 million people belonging to the four priority groups are to be vaccinated with either of the two vaccines for free.

The Ahmedabad-based Zydus Cadilla only recently got the regulatory permission to carry out phase-3 trial and has to begin the recruitment, while the Hyderabad-based Biological E is yet to reach that stage. It is unclear if Dr. Reddy’s Laboratory has completed enrolment for phase-3.

Challenges in recruiting

In a webinar hosted by DBT on December 31, Krishna Mohan, Executive Director of Bharat Biotech, had mentioned about the challenges in recruiting participants for phase-3 trial, as many felt they had only a 50% chance of getting the candidate vaccine. The news about vaccines soon becoming available made the recruitment even more challenging.

Pankaj Patel, Chairman of Zydus Cadilla said during the webinar that he anticipates difficulties in quick recruitment of volunteers but not with recruitment per se. “There are enough people committed to helping clinical studies. It might take longer but there won’t be a challenge with recruitment,” he said.

Effects of approval

Now, with two vaccines approved for restricted use, how much more challenging will it be to enrol participants for clinical trials, particularly phase-3 trials that need 25,000–30,000 people? “I think it would be more challenging than earlier for this reason,” says virologist Dr. Shahid Jameel, Director of the Trivedi School of Biosciences at Ashoka University.

Neurovirologist Dr. V. Ravi, formerly with NIMHANS, too, agrees that it would be challenging to recruit participants now. But says that DBT is addressing this through a call for research proposals for enhancing capacity for conduct of clinical trials for COVID-19 vaccine candidates.

Dr. Jameel also points out other challenges in recruiting participants now. “With the daily cases coming down, many people who would have volunteered would not see the urgency now as earlier. Also, with increasing numbers of infected people, there would be a reduced pool of susceptible people. Prior infection is an exclusion criterion,” he says.

Issues with slow spread

With the number of daily fresh cases slowing down since mid-September despite the winter and festival season, the spread of the virus appears to be slowing down. This raises an altogether different challenge in carrying out phase-3 trials where the efficacy of the vaccine is measured by comparing the number of COVID-19 cases and the kind of protection offered in participants in the vaccine arm vis-à-vis the placebo arm. China had to rely on other countries to carry out phase-3 trials of its vaccines as the virus spread had slowed sharply.

“It is going to be a challenge, mostly because of the requirement of certain cases to develop in the trial after vaccine administration to understand efficacy,” says Dr. Giridhara Babu, epidemiologist at the Public Health Foundation of India, Bengaluru. “It is best to recruit participants based on an antibody test, and have two distinct groups of people to participate (both infected and susceptible) in trials to understand the efficacy in both groups. This will ensure reaching the sample size efficiently.”

Professor of Microbiology at CMC Vellore, Dr. Gagandeep Kang says vaccine manufacturers can carry out phase-3 trials outside India and efficacy results from such trials would be accepted by the Indian regulator for vaccine approval.

Health-care workers are relatively better informed of clinical trials and are more likely to participate in trials. However, with the government vaccinating them on priority, this section of potential participants will now hesitate to take part in COVID-19 trials. Dr. Jameel sees another reason why health-care workers would hesitate to participate in trials when they have been prioritised to get the vaccine. He says: “Why would health-care workers participate if they are at high risk of infection, in line of vaccination, but have only a 50% chance of getting a vaccine?”

Testing younger people

Older people are particularly at risk of developing severe disease, and even dying, compared with younger people. That is precisely the reason why people over 50 years are one of the four high-risk groups to get the vaccine on priority. Since vaccines would become available in the market only after the government finishes vaccinating the priority groups, which would take many months, will trials be able to recruit only younger people?

Less than ideal

Only in an ideal situation will 100% of older people get vaccinated on priority. There will always be a certain percentage of older people who might be missed. Enrolling such people then depends on individual trial sites, says Dr. Ravi.

Dr. Jameel says, “Yes, younger people can be induced to participate in phase-3 trials. But the vaccine will then only be tested largely in a young and generally healthy group, unlike the population it would target when approved.”

Serum Institute suing a Covishield trial participant for ₹100 crore has surely not helped in encouraging people to participate in trials. “That was a public-relations disaster. The picture that emerged was a company abandoning and threatening a trial participant who volunteered initially for no monetary gain,” says Dr. Jameel. Dr. Babu says the behaviour of the company was akin to intimidating the participant. “It would have been ideal for the manufacturer, data safety and monitoring board or regulator to speak about this incident to enthuse confidence in potential participants,” Dr. Babu says.

Guinea pigs

Ignoring the special challenges that companies now face in conducting COVID-19 vaccine trials in India, participation in trials has not been a high priority for people in India. “People still view participating in clinical trials as being guinea pigs and we have done nothing to address the trust issues relating to clinical research. We are now seeing significant problems in recruitment in Phase-3 trials because our communication strategies about clinical research tend to be very limited,” Dr. Kang said during the webinar.

“I think the problem is in ensuring proper communication regarding the trials. We need good communicators, who are as good or even better than the scientists who do the trials,” says Dr. Babu. Dr. Ravi too agrees saying that lack of awareness is the main reason for hesitancy. “Well designed communication strategies providing correct information and engagement with all stakeholders in the community is what is needed to address this challenge,” says Dr. Ravi.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.